Fate Therapeutics Reports Significant Clinical Progress and Financial Stability

Fate Therapeutics shares are trading higher after the company announced significant advancements in its clinical programs, including promising FT819 CAR T-cell data in autoimmune diseases, and extended its operating runway through 2027 with $249 million in cash and investments.